[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Raymond James Equity Research [@RJResearch](/creator/twitter/RJResearch) on x 1611 followers Created: 2025-07-02 14:05:16 UTC Gary Nachman published, "BioPharma|Key Insights From KOL Call on Several Areas of Interest in Immunology, Allergy, and Asthma" following his investor call with a high-volume Allergist-Immunologist, with takeaways for $ADMA $IONS $AQST $EPRX and $AMGN XXXXX engagements  **Related Topics** [$eprx](/topic/$eprx) [$aqst](/topic/$aqst) [investment](/topic/investment) [$adma](/topic/$adma) [$ions](/topic/$ions) [$amgn](/topic/$amgn) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/RJResearch/status/1940411455989280885)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Raymond James Equity Research @RJResearch on x 1611 followers
Created: 2025-07-02 14:05:16 UTC
Gary Nachman published, "BioPharma|Key Insights From KOL Call on Several Areas of Interest in Immunology, Allergy, and Asthma" following his investor call with a high-volume Allergist-Immunologist, with takeaways for $ADMA $IONS $AQST $EPRX and $AMGN
XXXXX engagements
Related Topics $eprx $aqst investment $adma $ions $amgn stocks healthcare
/post/tweet::1940411455989280885